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Abstract.
Although there are various types of cancer treatments, none of these
currently take into account the effect of ageing of the immune system
and hence altered responses to cancer. Recent studies have shown that
in vitro stimulation of T cells can help in the treatment of patients.
There are many factors that have to be considered when simulating an
organism’s immunocompetence. Our particular interest lies in the study
of loss of immunocompetence with age. We are trying to answer questions
such as: Given a certain age of a patient, how fit is their immune system
to fight cancer? Would an immune boost improve the effectiveness of a
cancer treatment given the patient’s immune phenotype and age? We
believe that understanding the processes of immune system ageing and
degradation through computer simulation may help in answering these
questions. Specifically, we have decided to look at the change in numbers
of naive T cells with age, as they play a important role in responses to
cancer and anti-tumour vaccination. In this work we present an agent-
based simulation model to understand the interactions which influence
the naive T cell populations over time. Our agent model is based on
existing mathematical system dynamic model, but in comparisons offers
better scope for customisation and detailed analysis. We believe that
the results obtained can in future help with the modelling of T cell
populations inside tumours.
1 Introduction
According to estimations, over a million cases of colorectal cancer are diagnosed
annually. This type of cancer is also the second most common cause of cancer-
related deaths. Despite many different types of cancer treatments, survival rates
are low and remain between 50% and 10%, depending on the cancer stage.
However, none of the actual treatments take into account the patient’s immune
fitness or the immune system’s capability to respond to cancer.
Recent research [1, 2] shows success in laboratory stimulation of T cells that
kill tumour cells. However, in real patients there are additional factors to be con-
sidered before the stimulation. It is necessary to understand the patient’s ability
to respond to the treatment. Clinical trials are important, but not necessarily
the end point. Therefore further investigation is necessary to determine all the
factors to be observed before anti-tumour vaccination. We believe that one of
the factors that should be considered is immunocompetence with age. Therefore,
we want to investigate if we can use computational simulation models to verify
if the immune responses to cancer changes in different life stages.
With age there is a decay of the immune system’s performance resulting in
degenerative diseases and deregulated and ineffective responses. The ageing of
the immune system is called immunosenescence. Following an extensive study of
the immunosenescence literature, we point out the four most influential theories
in section 2. All four theories seem to be good candidates for developing im-
munosenescence simulation models. The four theories are: lack of naive T cells,
immunological space filling with memory cells, innate system up-regulation and
accumulation of T-regulatory cells.
The objective of our work is to find out if there is the possibility to predict
what actually is going to happen if a patient with a certain age is anti-tumour
vaccinated. To build such a computer simulation, one of the above theories has
to be chosen first, as they are not all mutually compatible. We will discuss later
in more detail why we believe that the first theory is the most appropriate one to
be used in cancer simulation models: T cell populations are a major contributor
to the immune system’s functionality. They also play a very important role in
responses to cancer and anti-tumour vaccination.
In this paper, we present results of our simulation model showing the inter-
actions which influence the naive T cell populations over time. The model is
based on the mathematical equations defined in [3]. In their work, Murray et
al. [3] propose a model with a set of equations to fit some observed data and
they try to estimate the likely contribution of each of the naive T cell repertoire
maintenance methods. Therefore, we believe that the results of this model could
be used as an input to a bigger model involving T cells inside tumours.
The work is organized as follows. Section 2 presents the immunological con-
cepts related to immune system ageing. Next, in Section 3, there is a summary
of the main theories that could be used for computational modelling. In Section
4 we present the model studied and its results. Finally, we draw conclusions and
present future steps of this research in Section 5.
2 Background
According to Bulati et al [4], ageing is a complex process that negatively impacts
on the development of the immune system and its ability to function. Progressive
changes of the innate and adaptive immune systems have a major impact on the
capacity of an individual to produce effective immune responses.
The decrease of immunocompetence in the elderly can be envisaged as the
result of the continuous challenge of the unavoidable exposure to a variety of
potential antigens, e.g. viruses, bacteria, food and self-antigens [5]. Antigens are
the cause of persistent life-long antigenic stress, responsible for the filling of the
immunological space by an accumulation of effector T cells and immunological
memory [5].
With age, there is also a significant reduction of naive T cells numbers caused
by the involution of the thymus. This situation eventually leaves the body more
susceptible to infectious and non-infections diseases [3]. Also, there is evidence
that clonotypical immunity deteriorates, while ancestral innate or natural im-
munity is conserved or even up-regulated [5, 6].
2.1 Some Factors Related to Immunosenescence
According to Franceschi [5], some factors that characterise immunosenescence
are the accumulation of memory T cells, the decrease and exhaustion of naive
T cells and a marked reduction of the T cell repertoire. Bulati [4], on the other
hand, believes that both innate and adaptive immunity are usually involved in
the pathogenesis of chronic age-related diseases like arthritis, atherosclerosis,
osteoporosis, diabetes and so on. However, the innate immune system appears
to be the prevalent mechanism driving tissue damage associated with different
age-related diseases [4]. Thus, ageing is accompanied by an age-dependent up-
regulation of the inflammatory response, due to the chronic antigenic stress that
impinges throughout life upon innate immunity, and has potential implications
for the onset of inflammatory diseases. Bulati points out some further important
factors related to ageing:
– There is evidence of neuromuscular degenerative disease and other tissue
dysfunction.
– Micronutrient inadequacy leads to metabolic consequences, e.g. DNA dam-
age, cancer, severe infection, cognitive dysfunction and accelerated ageing.
– Reactivity of dendritic cells to self antigens can be characteristic of ageing.
Furthermore, this over-reactivity induces T lymphocyte proliferation with
subsequent higher risk of autoimmune diseases.
– Hyper activated T cells are possibly involved in bone loss associated with
vascular disease in aged mice.
– There is a decrease in vaccine responsiveness leading to mortality.
De Martinis [7] and Franceschi [5] state that the most important charac-
teristics of immunosenescence are the accumulation of memory and effector T
cells, a reduction of naive T cells, shrinkage of the T cell repertoire and filling
of immunological space. He points out that:
– The filling of the immunological space with memory and effector cells is a
consequence of exposure to a variety of antigens over time.
– Clonal expansion of peripheral T cells carrying receptors for single epitopes
of the herpes viruses Cytomegalovirus and Epstein-Barr virus are common
in the elderly and are associated with a loss of early memory cells, an in-
crease of T cytotoxic cells, a gradual filling of immunological space and an
immune risk phenotype. The immune risk phenotype is a set of bioparame-
ters associated with poor immune function. These parameters are: low levels
of B cells, increased levels of cytotoxic T cells, poor T cell proliferative re-
sponse, a T helper - T cytotoxic ratio of less than 1 and cytomegalovirus
seropositivity [8].
– With the decline of immune function there is an increase in autoantibody fre-
quency. An important result of this may be a loss of the ability to distinguish
between self/nonself molecules.
– The lifelong respiratory burst, i.e. a reactive oxygen species causes damage to
important cellular components (lipidic membranes, enzymatic and structural
proteins and nucleic acids) during ageing. Oxidative damage is counteracted
by several genetically controlled enzymatic and non-enzymatic antioxidant
defence systems. All these protective mechanisms tend to become less effec-
tive with age.
– An elderly immune system becomes more predisposed to chronic inflamma-
tory reactions and less able to respond to acute and massive challenges by
new antigens. This continuous attrition is caused by clinical and sub-clinical
infections, as well as the continuous exposure to other types of antigens,
is likely responsible for the chronic innate immune system activation and
inflammation.
– Inflamm-ageing, the peculiar chronic inflammatory status which character-
izes ageing, is under genetic control and is detrimental to longevity. It leads
to long term tissue damage and is related to an increased mortality risk.
– The unavoidable chronic overexposure to stress factors determines a highly
pathogenic sustained activation of the stress-response system leading to a
progressively reduced capacity to recover from stress-induced modifications.
3 Candidates for Immunosenescence Models
We decided to select the four most influential theories from the above as possible
candidates for building computationally predictive systems and will now discuss
them in more detail. The four theories are: a lack of naive T cells, immunological
space filling with memory cells, innate system up-regulation and accumulation
of T-regulatory cells.
3.1 Lack of Naive T Cells
Before an individual reaches the age of 20, the set of naive T cells is sustained
primarily from thymic output [3]. However, in middle age there is a change
in the source of naive T cells: as the thymus involutes, there is a considerable
shrinkage in its T cell output, which means that new T cells are mostly produced
by peripheral expansion. There is also a belief that some memory cells have their
phenotype reverted back to the naive cells type [3].
However, these two new methods of naive T cell repertoire maintenance are
not effective [3] as they do not produce new phenotypic changes in the T cells.
Rather, evidence shows that they keep filling the naive T cell space with copies
of existing cells. Therefore, the loss of clones of some antigen-specific T cells be-
comes irreversible. These age-related phenomena lead to a decay of performance
in fighting aggressors.
3.2 Space Filling
The immune system deteriorates with age by losing functionality and immuno-
competent cells. Moreover, it becomes limited in its use of resources. There is
a finite number of T cells in operation at any time and to work properly, the
immune system needs a reserve of naive T cells to combat new intrusions, and
memory cells for previously encountered antigens.
With age, the repertoire of naive T cells shrinks proportionately to the pre-
viously faced threats, while memory cell numbers increase [3, 7, 5]. Late in life
the T cell population becomes less diverse and some antigen-specific types of T
cell clones can grow to a great percentage of the total T cell population, which
takes up the space needed for other T cells, resulting in a less diverse and in-
effective immune system. At some point there are not enough naive T cells left
to mount any sort of effective defence and the total repertoire of T cells is filled
with memory cells.
3.3 Innate Up-regulation
With age there is a decay in adequate functioning of the main phagocytes, i.e.
macrophages, neutrophils [9] and dendritic cells [10]. As a consequence, deregu-
lated immune and inflammatory responses occur in old people.
The investigation into the cellular and molecular mechanism underlying these
disorders has provided compelling evidence that up-regulated cyclooxygenase
and its product, particularly prostaglandin, play a critical role in the age-associated
disregulation of the immune and inflammatory responses [6]. Increased prostaglandin
production in old macrophages contributes to the suppression of T cell function
with ageing. Furthermore, interventions targeted at decreasing prostaglandin
production have been shown to enhance T cell-mediated function [6].
Thus, innate immunity and a high capacity to mount a strong inflammatory
response, which is useful at younger age can become detrimental later in life.
Inflamm-ageing can thus be considered a main phenomenon responsible for major
age-related diseases and the evolutionary price to pay for an immune system fully
capable of defending against infectious diseases earlier in life.
3.4 Accumulation of Treg Cells
The individual’s ability to mount an effective immune response can be limited
by regulatory elements such as significant changes in the number of T regulatory
(Treg) cells [11]. Treg cells act to suppress activation of the immune system and
thereby maintain immune system homoeostasis and tolerance. The accumula-
tion of Treg cells in old people inhibits or prevents some immune responses, e.g.
anti-tumoural ones. Also, the reduction of Treg cells might compromise the acti-
vation of immune responses in the aged. Therefore, an imbalance in Treg normal
functioning can predispose immune dysfunction. This results in a higher risk of
immune-mediated diseases, cancer or infections.
3.5 Discussion
A summary of the main characteristics of the candidate models described in the
previous sections is presented in Table 1.
Theories
Characteristics Lack of Naive Space Filling Innate Up-regulation Treg Cells
Shrinkage of naive cells × ×
Diversity decrease × ×
Few clones taking space × ×
Excessive memory cells ×
Loss of clones ×
Inflammation × ×
Excessive T suppression × ×
Degeneration × × × ×
Auto-immunity × × × ×
Less vaccine response × × ×
Table 1. Main characteristics of the candidate models.
Recent research [2] states that the stimulation of high-avidity T cell receptors
responses is essential for effective anti-tumour vaccines. High-avidity responses
are capable of efficient anti-tumour activity in vitro and in vivo. However, in
order to have effective vaccinations, there should be sufficient T cell response
around tumours.
As we have discussed, when the organism ages it lacks T cells. Thus, we would
like to know how critical immunosenescence is for T cell responses to anti-tumour
vaccination in cancer treatments. In order to proceed with this study, we have
chosen the first candidate model of immunosenescence, because it has the most
direct focus on T cells which have a direct relation to cancer immunocompetence.
The number and phenotypical variety of naive T cells in an individual repre-
sents one of the main factors highlighted as influence in the process of immunose-
nescence. This number changes with age in quantity and diversity. It is also one
of the first immune-components to show signs of ageing. Therefore, we believe
that T cell responses to cancer might deteriorate with age. By understanding
how T cell populations change over the years, we could get insights of what kind
of T cell response there will be inside tumoural sites and towards vaccination.
In order to understand T cells dynamics with time, we developed an agent
based simulation model presented in the next section. The simulation is based
on data and equations obtained in [3]. The future objective is to use this agent-
based model as an input for another model involving interactions of T cells and
cancer.
4 Model
In this section we present the conceptual model together with the mathematical
model and show how we transformed this into the agent based simulation that
we performed.
4.1 Naive T Cell Output
A good indicator of thymic contribution to naive T cell output in an individual
is the level of a particular biological marker called ’T cell receptors excision
circle’ (TREC). TREC is some circular DNA formed during the coding of T-
cell receptors. The TREC percentage on a T cell decays with shrinkage of the
thymic output and with the activation and reproduction of naive T cells [3]. This
means that naive T cells originating from the thymus have a greater percentage
of TREC than those originating through other proliferation.
Our model proposed here is based on data and equations obtained from [3],
which is concerned with understanding naive T cell repertoire dynamics. The
objective of Murray’s model is to determine the likely contribution of each source
of naive T cells, by comparing estimates of the presence of TREC in these cells
(see Figure 1). The dynamics of the sustaining sources, i.e. naive proliferation,
TREC and reversal of memory to naive T cells are each modelled mathematically.
Fig. 1. Dynamics of Naive T cells.
4.2 The Mathematical Model
The mathematical model proposed in [3] is described by the equations (1) to (7)
below. In these equations, N is the total number of naive cells of direct thymic
origin, Np is the number of naive cells that have undergone proliferation, A is
the number of activated cells, M is the number of memory cells and t is time (in
years). The first differential equation is:
dN
dt
= s0e−λtts(Np)− [λn + µng(Np)]N, (1)
where: s0 is the thymic output ; λt is the thymic decay rate, s0e−λtts(Np) rep-
resents the number of cells that arise from the thymus where s(Np) is the rate
of export of the thymus defined by:
s(Np) =
1
1 + s¯
Np
N¯p
(2)
As in the beginning of life there are no naive cells from proliferation, i.e.
Np, this parameter will have no influence on the output of the s function and
therefore also no influence on the death rate of naive cells from the thymus. This
can be better understood when we substitute Np by a number close to zero in
the equation:
S(Np) = 1/(1 + s¯Np/N¯p) = 1/(1 + 0(number→0)/392) ∼= 1.
Also, λnN represents the naive cells’ incorporation into the naive proliferat-
ing pool, where λn is the naive proliferation rate, µn is the thymic naive cells
death rate, µng(Np)N represents the naive cell death rate where the function
g(Np) is the rate of change between naive TREC-positive and naive TREC-
negative, defined as:
g(Np) = 1 +
bNp
N¯p
1 + Np
N¯p
, (3)
N¯p and s¯ are equilibrium and scaling values respectively.
For the simulation, s0 was defined as:
s0 = 0.82(7024e(−((t−12.02)/3.623)
2) + 5.203× 105e(−((t+127.8)/64.47)2)+
1937e(−((t−7.357)/6.03)
2) + 1.259× 1018e(−((t−1309)/214.4)2))
The second differential equation is:
dNp
dt
= λnN + [ch(N,Np)− µn]Np + λmnM (4)
where: c is the proliferation rate, ch(N,Np)Np represents the naive proliferation
where h(N,Np) is the dilution of thymic-naive cells through proliferation defined
by:
h(N,Np) =
1
1 + N+Np
N¯p
(5)
µnNp is the death rate of naive cells originated from proliferation and λmn is
the reversion rate from memory into Np. The differential equation for memory
cells (M) is:
dM
dt
= λaA− µmM − λmnM, (6)
where: λa is the reversion rate into memory and µm is the death rate of memory
cells.
The final differential equation concerns the active cells (A) and is:
dA
dt
= λNaN + λNpNp− (λa + µa)A. (7)
where: λNa is the activation rate of naive cells from the thymus (N). As we
know, these cells have to proliferate before being activated. Therefore λNa was
set to zero. λNpA is the activation rate of the naive cells from proliferation (Np).
µa is the death rate of active cells set to 44.4 given their short life span.
All rate values and other parameters for the model can be seen in Table 2.
The values for these rates and parameters have been obtained by [3], through
sensitivity analysis and parameter optimisation of the model. These parameter
values, when used in conjunction with the above mathematical model, produced
the results that most closely matched real-life observations of cell numbers[3].
Thus we use the same rates and parameter values in our model.
parameter value(s)
λt
log(2)
15.7
(year−1)
λn 0.003
µn 4.4
c µn(1 +
700
N¯p
)
λmn 0
µm 0.05
λNa 0
λNpA 0.1
s 0
λn 0.003
λmn 0
Np 392
b 4.2
Table 2. Parameter values for the mathematical model.
In the next section, we will show how we can build an agent-based model rep-
resenting equations (1) to (7) in order to investigate if it is possible to reproduce
and validate the results obtained by [3].
4.3 The Agent Based Model
To convert the conceptual model into an agent based model, we first have to
decide on what are the agents and their states: T cells are the agents and can
assume four states, i.e. naive, naive from proliferation, active or memory. The
agents’ state changes and their death are defined by the ratios given in the math-
ematical model. Initially, all the agents are in the naive state. As the simulation
proceeds, they can assume other stages according to the transition pathways
defined in the conceptual model of figure 1.
The simulation scenario studied alters the function g over time by setting
the parameter b greater than zero (b = 4.2). This means that the death rate of
naive T cells from thymus will increase through the years as the number of naive
cells from peripheral proliferation increases. There is no change of the thymic
export, no reversion from memory to a naive phenotype and the conversion rate
of naive cells from thymus to naive cells from proliferation is low (equal to 0.003).
The simulation was run for a period of one hundred years and it considered the
impact of thymic shrinkage per mm3 of peripheral blood and 2000 initial naive
cells from thymus.
The data collected for validation is plotted in the graph shown in Figure
2. The results from the simulation can be seen in Figure 3. The results show
three different curves representing naive T cell populations derived from the
thymus, peripheral naive T cells and the total number of naive cells. The curve
representing naive cells from the thymus presents decay at the beginning of life
followed by some interval of stability. By the age of twenty, the thymic export
decreases following an exponential trend.
The results show that with the decay of naive cells derived from thymus, the
naive repertoire changes from the thymic source to the peripheral proliferation
source. And although the numbers of naive cells tend to be stable over time, there
is no new phenotypical naive cell entering the system. This phenomenon rein-
forces the ideas of clone degeneration and space taken over by a few phenotypic
clones.
As an extrapolation of the model, if we consider that around ten percent of
the total T cell population is active in the organism during its lifetime, we can
roughly get an idea of the behaviour of memory cells over time. This behaviour
is shown in figure 4.
5 Conclusions
New trials to combat cancer are intending to take into account the individual
patient’s tumour biology and immune responses. In vitro stimulation of effector
T cells has shown success in tumour treatments. To proceed with anti-tumour
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Fig. 2. The dataset used for validation was provided by [3] and [12].
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Fig. 3. Results for the agent based simulation.
vaccinations in vivo it is necessary to determine the patient’s immunocompetence
profile. We believe that this profile and the patient’s ability to fight cancer
is influenced by immunosenescence and can be computationally modelled and
simulated.
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Fig. 4. Estimations of the amount of memory T cells with age.
We have shown in this paper how important factors related to immunosenes-
cence that have a direct influence on T cell responses to cancer and vaccination
can be investigated in a simulation model. In our research, the aim is to estab-
lish correlations between age, T cell populations and cancer immunocompetence.
What we have done to date is to understand how T cell populations change with
time.
The simulation model that we built and studied is based on mathematical
equations converted into an agent based simulation. Results fit the observed
data and thus we can estimate the likely contribution of each of the naive T cell
repertoire maintenance method. With the decay of naive cells derived from the
thymus, the naive repertoire changes from the thymic source to the peripheral
proliferation source. The numbers of naive cells tend to be stable over time,
but there is no new phenotypical naive cell entering the system. The lack of
new T cell phenotypes probably makes vaccination and responses to cancer less
effective. We believe that the results of this model could be used as an input to
a bigger model, involving the movements of T cells inside tumours.
We could have built other types of simulation models based on the math-
ematical equations, and indeed have done so elsewhere, e.g. we have built a
system dynamics model of the same problem for the 2010 Summer Simulation
conference. Building a system dynamics simulation is a more straightforward
task, as it readily lends itself to simulating differential equations. Agent-based
models on the other hand require different conceptual models, including states
and their transitions. This is non-trivial, but agent-based models do have the
advantage of being more flexible. For instance, in future we intend to extend the
model to include notions of space and movement (e.g. inside a tumour). Such
additions are not easily possible when using other simulation paradigms. More-
over, agent-based simulations do not only work on an aggregate level, i.e. it is
also possible to follow individual cells. We believe this point will hep us not only
in our understanding and validation of future models, but also assist us in our
explanations to non-computer scientists.
In order to move this research forward, the model needs to be extended
to address the interactions between T cells and tumoural cells. We want to
investigate how T cells would respond to vaccination and fight tumoural cells.
We also want to look at the individual behaviour of T cells inside different types
of tumours and cancers. Therefore, we believe that the choice of an agent-based
model is the most suitable for our future work. Other future questions we intend
to answer include the usability of the simulation by clinicians and which model
would be more suitable for their understanding of the underlying immunology.
Specifically to continue the cancer model, we intend to use the actual math-
ematical model as part of a bigger set of equations representing T cell responses
inside tumours. Data about T cell responses in colorectal cancer has been col-
lected and will be used for a new mathematical model. Once we have estab-
lished how T cells respond to cancer and stimulation, an additional factor will
be added. We will consider the influence of age in quantity and quality of re-
sponses. We believe that this model could provide clinicians with information
about the suitability and advantages of cancer vaccination in patients with a
particular immunocompetence profile.
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